Maravai LifeSciences (MRVI) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $73.4 million, up 6.5% year-over-year, with adjusted EBITDA of $16.9 million and a net loss of $14.5 million; Nucleic Acid Production contributed $58.5 million and Biologics Safety Testing $14.9 million.

• Adjusted EBITDA margin for Q2 was 23%, with gross margin improving to 47.9% from 37.2% in Q2 2023.

• Cash and cash equivalents at quarter-end were $573 million, with $530 million in gross debt, resulting in a $43 million net cash position.

• Strategic progress included new product launches, facility milestones at Flanders 1 and 2, and expanded partnerships in RNA therapeutics.

• Continued investment in R&D, infrastructure, and execution on return-to-growth strategy.

Financial highlights

• Q2 2024 net loss was $14.5 million, compared to $11.9 million in Q2 2023; adjusted EBITDA improved to $16.9 million from $9.1 million.

• Six-month revenue was $137.6 million, down 7.0% year-over-year; six-month net loss was $37.2 million, adjusted EBITDA $24.7 million.

• Q2 2024 gross margin was 47.9%; net loss per share was $(0.05); adjusted EPS was $0.00.

• Cash provided by operations was $17 million in Q2; capital expenditures net of BARDA reimbursements were $6 million.

• Fully diluted share count was 254 million in Q2.

Outlook and guidance

• 2024 revenue guidance remains $265 million–$285 million, with adjusted EBITDA margin expected at 20%–22%.

• H2 2024 revenue expected at $137 million midpoint; H2 margin expected around 24%.

• Full-year adjusted EPS expected between a $0.02 loss and a $0.08 loss per share.

• Net capital expenditures for 2024 projected at $30 million.

• Adjusted effective tax rate for 2024 set at 24%.